A number of surprises could rock the biotech market, so analysts at the investment bank Cowen worked to take them into account before they transpired.
In August, the US Patent and Trademark Office launched a review of the patents for Soliris, Alexion's blockbuster rare blood disease drug, after rival Amgen requested a challenge to the company's patents on the drug. "With a number of other gene therapies for Hemophilia A in or entering clinical trials, why wouldn't patients wait a few years to see if there is one with a better profile? It is hard to see how the adoption of valrox won't be glacial," Cowen analysts noted as the consensus view.
For instance, in defending the $1,000-a-pill price tag of the hepatitis C treatment Sovaldi, Gilead could argue that it was looking to recoup on its investment, which largely included the $11.2 billion acquisition of Pharmasset, the company that initially developed Sovaldi.Despite what the past year has been like for big biotech companies like Celgene, Biogen, Amgen, and Gilead, a surprise that could happen in 2020 might be that these drugmakers make a comeback.
, and the potential to introduce certain strains of bacteria to enhance responses to treatments. Though most research into treatments targeting the microbiome still hasn't made it past early trials, the analysts wrote that the results so far "provide reasons to be encouraged by single-strain approaches in these oncology settings."5.
대한민국 최근 뉴스, 대한민국 헤드 라인
Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.
출처: BusinessInsider - 🏆 729. / 51 더 많은 것을 읽으십시오 »
출처: BusinessInsider - 🏆 729. / 51 더 많은 것을 읽으십시오 »
출처: Forbes - 🏆 394. / 53 더 많은 것을 읽으십시오 »
출처: BusinessInsider - 🏆 729. / 51 더 많은 것을 읽으십시오 »
출처: BusinessInsider - 🏆 729. / 51 더 많은 것을 읽으십시오 »